GlassScriptPhysician profile
Craig E Crismon
NPI 1396702882
$1,969.94
in general payments reported to CMS, 2019-2025
30 companies · $98.22 in 2025
The $98.22 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $248 · 2021: $410 · 2022: $472 · 2023: $281 · 2024: $358 · 2025: $98.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $423.90 | 2020-2024 | Prolastin-C Liquid |
| Lilly USA, LLC | $260.73 | 2021-2025 | Mounjaro, Basaglar, Trulicity |
| Novo Nordisk INC | $162.11 | 2020-2024 | Wegovy |
| Abbott Laboratories | $134.30 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $118.35 | 2019-2024 | Xarelto |
| Dexcom, INC. | $92.47 | 2021-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $85.86 | 2019-2024 | Evenity, Prolia |
| Daiichi Sankyo INC. | $73.58 | 2022-2024 | Injectafer |
| Eisai INC. | $72.36 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $59.82 | 2019 | |
| Amarin Pharma, INC. | $48.53 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $45.42 | 2022-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Sentynl Therapeutics, INC. | $40.00 | 2022 | |
| Medtronic, INC. | $36.82 | 2022-2024 | Minimed 780g |
| Abbvie INC. | $34.29 | 2022-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $32.10 | 2021 | |
| Insulet Corporation | $31.96 | 2025 | Omnipod |
| Genentech USA, INC. | $30.27 | 2020 | |
| Abiomed | $25.68 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.58 | 2019-2020 | |
| Pfizer INC. | $19.08 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $17.58 | 2020 | |
| Glaxosmithkline, LLC. | $15.75 | 2024 | Arexvy, Bexsero, Shingrix |
| Sanofi-Aventis U.S. LLC | $15.59 | 2021 | |
| Astellas Pharma US INC | $15.18 | 2024 | Veozah |
| Collegium Pharmaceutical, INC. | $13.97 | 2025 | Jornay Pm |
| Actelion Pharmaceuticals US, INC. | $13.81 | 2024 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $13.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.86 | 2022 | |
| Electromed, INC. | $1.93 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Crismon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.